key: cord-0742930-bnev9n7r
authors: Gabbai‐Armelin, Paulo Roberto; de Oliveira, Analú Barros; Ferrisse, Túlio Morandin; Sales, Luciana Solera; Barbosa, Elis Rodrigues Oliveira; Miranda, Marina Lins; Salomão, Karina Borges; Brighenti, Fernanda Lourenção
title: COVID‐19 (SARS‐CoV‐2) infection and thrombotic conditions: A systematic review and meta‐analysis
date: 2021-04-14
journal: Eur J Clin Invest
DOI: 10.1111/eci.13559
sha: a634d38d7d815f6687f5ac830fdb1ed69cdededd
doc_id: 742930
cord_uid: bnev9n7r

BACKGROUND: COVID‐19 is an infectious disease caused by SARS‐CoV‐2 associated with haematological manifestations (thrombolytic events). AIMS: Considering the high prevalence of the thrombotic scenarios associated with COVID‐19, the aim of this study was to perform a systematic review of the available literature, concerning the relation of COVID‐19 and the thrombotic events, and identify prognostic factors for these events. MATERIALS & METHODS: PubMed, Web of Science and Scopus databases were searched. Independent reviewers conducted all flow diagram steps. For qualitative analysis, Oxford level of evidence and Newcastle‐Ottawa scale were used in the eligible articles. For the prognostic factors, a meta‐analysis was conducted to age, number of neutrophils and platelets, and levels of ferritin, C‐reactive protein, lactate dehydrogenase and D‐dimer. Publication bias was accessed by funnel plot and by trim‐and‐fill test. Trim‐and‐fill test was also applied to evaluate meta‐analysis bias. RESULTS: Twenty articles were included in the qualitative analysis, and 6 articles were included in the meta‐analysis. Case‐control studies showed bias related to exposure, and the main bias in cohort studies were related to selection and outcome. All articles received score 4 for the level of evidence. Hypertension and diabetes were the comorbidities more frequently associated with thrombolytic events. Significant results were found regarding D‐dimer (P < .0001) and age (P = .0202) for thrombotic events in patients diagnosed with COVID‐19. CONCLUSION: Patients older than 60 years, with hypertension, diabetes and D‐Dimer values above 3.17 µg/mL, can be considered prognostic factors for developing thrombotic events due to COVID‐19.

The coronavirus disease 2019 (COVID- 19) is an infectious disease that affects the human respiratory system, and it is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 The first cases of this disease were reported in Wuhan, China, and it spread rapidly in more than 180 countries, threatening the health of millions of people. Based on that, the World Health Organization (WHO) has considered this disease an emergency global public health problem. 2, 3 In this context, COVID-19 has been extensively studied, motivating the development of new researches, products and clinical approaches.

The clinical characteristics of COVID-19 may vary from asymptomatic infections to more severe conditions. The mild symptoms include fever, fatigue, cough, sore throat, nasal congestion and headache. In more complicated cases, manifestations of pneumonia can be observed based on imaging examinations. Subsequently, in more severe cases, the symptoms are shortness of breath, with lesions that can affect more than 50% of the lung. The clinical pattern with rapid progression found in some patients affected with COVID-19, if not quickly reversed, may lead to respiratory failure. In this case, mechanical ventilation is needed, and patients might perish. 3, 4 Coagulation disorders and thrombotic events have been reported in patients that presented the severe pattern of COVID-19. 1 SARS-CoV-2 may cause damage to the endothelial tissue, leading to coagulation alterations in patients affected by this disease. 5-7 SARS-CoV-2 accesses the endothelial cell through the binding, via spike protein envelope, with angiotensin-converting enzyme 2 (ACE-2) which is present on the cellular membrane of the endothelial cells. 8 It is suggested that the infection by SARS-CoV-2 promotes, via NADPH enzyme activation path, an increased expression of the platelet tissue factor. The tissue factor may interact with VII factor of the coagulation cascade, triggering the extrinsic via of coagulation and, finally, resulting in the thrombin and fibrin production. 8 Nevertheless, the exact mechanism that lead to the coagulation alterations was not totally clarified. 5 Several studies [5] [6] [7] [8] reported a strong relation between the occurrence of thrombotic events and SARS-CoV-2 infection. Helmes et al 5 and Fraissé et al 6 described, respectively, the prevalence of thrombotic events in 42.6% and 40% of the investigated patients. Considering the prevalence of the thrombotic events associated with COVID-19, the aim of this study was to perform a systematic review of the literature, concerning the relationship between COVID-19 and thrombotic events. Secondly, we evaluated possible prognostic factors (age, D-dimer, Creactive protein, ferritin, lactate dehydrogenase, platelets and neutrophils numbers) for thrombotic events in patients affected by COVID-19.

The systematic review was performed conforming to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines 9 and according to broad Enhancing the Quality and Transparency of Health Research (EQUATOR) guidelines, 10 and registered at PROSPERO (#CRD42020199814). The study intended at responding the query: What are the clinical implications of COVID-19 (SARS-CoV-2) regarding thrombotic conditions? This query was established based on the 'PECO' strategy for systematic review 11 in which P (patients affected with COVID- 19) , E (presence of thrombotic events in patients diagnosed with COVID- 19) , C (absence of thrombotic events in patients diagnosed with and O (clinical aspects and possible prognostic factors in patients affected with COVID-19 disease associated with thrombotic events).

The inclusion criteria for the systematic review were (a) observational human studies, such as case-control, cohort and cross-sectional studies; (b) studies associated explicitly to COVID-19 disease related to the presence of thrombotic events; and (c) scientific articles written in English language.

In contrast, the exclusion criteria were (a) review articles, letters, individual ideas, book sections or congress abstracts; (b) case series studies and case reports; (c) in vitro and animal studies; (d) non-English languages articles (or inappropriate English level) and (e) articles that did not have their full-text easily accessible.

• The review adds important information about COVID-19 and its influence on thrombotic conditions, regarding risk and prognostic factors. • Patients older than 60 years, with comorbidity and D-dimer level above 3.17 µg/ mL, are at increased risk of developing thrombotic events due to COVID-19.

ROBERTO GABBAI-ARMELIN ET AL. 

PRISMA statement was followed for data assessment and extraction. 9 Basically, the following data were extracted from the papers: (a) sort of study; (b) sample size; (c) control group; (d) influence of COVID-19 (SARS-CoV-2) on thrombosis (including venous and arterial thrombotic events, thrombotic complications, cerebral and pulmonary thrombosis, hypercoagulability, haemorrhagic events and D-dimer levels); (e) main conclusions and outcomes. The quality analysis of the case-control and cohort studies was done based on the Newcastle-Ottawa scale. 12 The Level of Evidence (LoE) for each one of the investigations was determined according to the guidelines of the Oxford University Center for Evidence-Based Medicine. 13

For quantitative analysis, R software, version 3.6.1, 'META' package and Rstudio platform were used. In the meta-analysis, the results were showed in forest plot. Mean difference and fixed effect model were the parameters used to interpret the results. The I 2 test measured the heterogeneity among the studies. In addition, to access the publication bias, the funnel plot (n = 2) and the trim-and-fill method (n > 2) were used. Moreover, the trim-and-fill method was also applied to evaluate the meta-analysis bias, utilizing mean difference and random effect model as parameters, such as a sensitivity test. The significance level of 5% and the reliability level of 95% were selected for the statistical analysis. In this step, only articles that investigated patients diagnosed with COVID-19 (presence and/or absence of thrombotic events) were eligible to statistical analysis. In this sense, the variables studied were age, number of neutrophils and platelets, and levels of ferritin, C-reactive protein, lactate dehydrogenase and D-dimer.

The articles selection procedure is briefly presented in the flow diagram shown in Figure 1 . The initial electronic examination generated 310 articles. In total, 76 duplicate articles were removed; therefore, 234 articles were maintained in the study. 

ROBERTO GABBAI-ARMELIN ET AL. The optimal cut-off value of D-dimer to predict in-hospital mortality was 2.0 μg/ mL. D-dimer on admission higher than 2.0 μg/mL may predict in-hospital mortality in patients with COVID-19.

(Continues)

After the title and abstract screening, 202 articles were excluded, resulting in 32 articles which were selected for fulltext evaluation. Then, 20 articles were eligible to qualitative analysis and 6 articles were included in the meta-analysis (quantitative synthesis). Amongst the 20 eligible articles in the present systematic review, 7 of all of them were cohort studies (25% retrospective and 10% prospective), 11 casecontrol studies (40% retrospective and 15% prospective) and 2 investigations were cross-sectional studies (10%). Table 1 summarizes the characteristics and key results of the included articles.

Eighteen studies (86%) evaluated patients in the age group from 59.9 to 73.2 years. 5,6,14-29 Fu et al 30 investigated 75 patients within the mean age of 46.6 years and Panigada et al 31 did not present the age of patients. Among these studies, the mean age of patients affected by COVID-19 and without thrombotic events was 62.40 and the mean age of patients diagnosed with COVID-19 associated with thrombotic events was 63.78. 6, 14, [17] [18] [19] 24 Seventeen articles (85%) described comorbidities that were frequently associated with the inpatient care, such as hypertension 6 [19] [20] [21] 26 and obesity. 24, 25, 29 The frequency of these comorbidities was the same for patients affected by COVID-19 with and without thrombotic events.

Thirteen studies (65%) reported death tools. The fatality rate varied from 0% to 23.7%. Moreover, different therapeutic approaches were described. Anticoagulants were used in 13 studies (65%). 6, [14] [15] [16] [17] [19] [20] [21] [22] [23] [24] [25] 27 Antiviral or corticosteroids were used in two studies (10%). 5, 29 Three studies did not mention any type of therapy. 18, 28, 31 Among these studies, only one evaluated the death tools in patients affected by COVID-19 associated with thrombotic events, being this rate of 40%. 18 Examinations that evaluated prognostic factors for thrombosis were used in some of the included studies. A total of 16 articles (80%) requested complementary examinations and 14 (70%) of them included D-dimer level for evaluating the thrombosis risk. 5, 14, [16] [17] [18] [19] [23] [24] [25] [26] [27] [28] 30, 31 Zhang et al 28 established that D-dimer levels higher than 2.0 μg/mL may correlate with hospital mortality in patients affected by COVID-19. In addition, Artifoni et al 14 suggested that D-dimer values ≥3.0 μg/mL could act as a prognostic factor for the development of thromboembolic events. Demelo-Rodríguez et al 19 and Ranucci et al 25 showed that patients with deep vein thrombosis (DVT) and thromboembolic complications have increased D-dimer levels (4.5 μg/mL and 5.5 μg/mL, respectively). Still to demonstrate the importance of D-dimer as a prognostic factor, Helms et al 5 observed that the majority of patients (>95%; n = 150) have increased Ddimer and fibrinogen levels.

Besides D-dimer level, other factors, such as oxygen saturation 15 ; levels of C-reactive protein, creatine kinase, lactate dehydrogenase and ferritin 16 ; Sequential Organ Failure Assessment (SOFA) score 17 ; neutrophil-to-lymphocyte ratio 24 ; fibrinogen levels and platelet count 25 

ROBERTO GABBAI-ARMELIN ET AL.

of neutrophil extracellular traps (NETs), 29 have been studied as prognostic factors for thromboembolic events. Imaging examinations, such as duplex ultrasonography, angiotomography 5, 14, 20, 21, 23 ; lower limb compression ultrasonography 17 ; chest computed tomography (CT), Doppler ultrasound 18, 19, 26 ; complete duplex ultrasound 22 ; and thromboelastography, 31 have been also performed for the evaluation of thrombotic conditions associated with COVID-19. Moreover, other types of evaluation were also utilized, such as haematology laboratory tests 6, 24, 25, [27] [28] [29] [30] and quantification of cell-free DNA/ quantification of Cit-H3/ quantification of MPO-DNA complexes. 29 Table 2 shows the outcomes of the quality analysis of the case-control and cohort studies based on the Newcastle-Ottawa scale. Additionally, all included scientific articles presented level of evidence 4, according to Oxford University Center for Evidence-Based Medicine criteria (Table 1 ).

In the case-control studies included in the present systematic review, the main bias was related to the exposure. The studies have failed in the sample size formation (very divergent) and details about the formation of the control and case groups. In addition, cohort studies presented bias associated with selection and outcome. Selection bias was associated with the lack of representativeness of the exposed cohort and with the lack of drawing the non-exposed cohort from a different source. Outcome bias was associated with the absence of the following information: follow-up and lost rates.

Articles that investigated possible prognostic factors of thrombotic events in COVID-19 patients were included. Almost all data collected in the eligible articles showed nonparametric data. Therefore, the mean was estimated according to Luo et al 32 and the standard deviation was estimated according to Wan et al. 33 COVID-19 patients with thrombotic events were 2.23 years older than COVID-19 patients without thrombotic events (P = .0493). The high level of heterogeneity (I 2 = 66%) made the data unreliable ( Figure 2A) . Additionally, the trimand-fill test identified two articles with possible publication bias, 14, 19 but no significant results were found (P = .1038) and the high level of heterogeneity (I 2 = 69%) remained ( Figure 2B ). After excluding the articles responsible for the high level of heterogeneity, an additional meta-analysis was conducted and showed significant results (2.83 years) (P = .0202). However, high level of heterogeneity was still found (I 2 = 77%) ( Figure 2C) .

No statistically significant results were found for platelet (P = .6904) and neutrophils (P = .2353) count and for levels of C-reactive protein (0.9838), lactate dehydrogenase (P = .4243) and ferritin (P = .2538) ( Figure 3A -F and Figure 4C-F) . A high level of heterogeneity (I 2 > 50%) was observed for platelet count, lactate dehydrogenase and ferritin. In contrast, the neutrophils count, and C-reactive protein level demonstrated low level of heterogeneity (I 2 < 50%). In addition, there were publication biases for lactate dehydrogenase levels ( Figure 3D ) and platelet count ( Figure 3B ). For platelet count, after the removal of one article, 19 an additional meta-analysis was performed, showing no significant results (P = .6594). Elevated levels (in the serum from COVID-19 patients) of cell-free DNA, myeloperoxidase-DNA (MPO-DNA), and citrullinated histone H3 (Cit-H3) were found. The latter 2 are specific markers of NETs. Cellfree DNA strongly correlated with C-reactive protein, D-dimer, and lactate dehydrogenase, as well as absolute neutrophil count. MPO-DNA associated with both cell-free DNA and absolute neutrophil count, while Cit-H3 correlated with platelet levels. These findings may indicate NETs as novel therapeutic targets in COVID-19.

D-dimer showed significant results in the meta-analysis (P < .0001). Patients with COVID-19 reached D-dimer levels up to 3.17 µg/mL, even with the absence of any thrombotic events. Low level of heterogeneity (I 2 = 48%) and inexistence of publication and meta-analysis biases were also observed ( Figure 4A ,B).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new type of respiratory transmitted virus. The coronavirus disease 2019 (COVID-19) pandemic is responsible for highly intensive care unit (ICU) admission rates and high fatality rate. 6, 18, 22, 28 Besides respiratory failure, coagulopathy and thrombosis are abnormalities that can occur in patients affected by COVID-19. 22 Previous works highlighted that the new coronavirus can activate inflammatory and thrombotic processes. In this scenario, mononuclear cells interact with activated platelets and with the coagulation cascade, which triggers inflammatory cells. The exacerbated inflammatory process due to COVID-19 infection, accompanied by the release of pro-inflammatory cytokines, lead to the impairment of the natural coagulation pathways.

In other words, this disease can be related with increased inflammatory cytokines and coagulation disorders, predisposing to the development of thrombus. 34, 35 Up to now, there is no correlation between the clinical behaviour of COVID-19 and the presence of thrombotic events. 36, 37 However, patients that presented coagulation abnormalities have a poor prognosis in COVID-19. 37 This fact expresses the need to establish reliable prognostic factors related to thrombotic events.

Among the findings in qualitative synthesis in the present systematic review, diverse clinical conditions-such as coagulopathy (as disseminated intravascular coagulation-DIC), thrombosis (including deep vein thrombosis (DVT)), venous thromboembolism (VTE), arterial TE (thrombotic events), pulmonary embolism (PE), as well changes in D-dimer level, fibrinogen and platelet count-were frequently associated to severe COVID-19 cases. 5, 6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 38 Moreover, comorbidities are factors associated with COVID-19 disease exacerbation. Gold et al 39 centrally considered a relationship between COVID-19 and comorbidities showed that hypertension, diabetes and respiratory diseases were prevalent in severe and fatal cases. In the present study, the most prevalent comorbidities found in patients with COVID-19 were cardiovascular diseases, 5, 16, 18, 28, 29 diabetes, 5, 6, 14, 16, 18, 23, [27] [28] [29] [30] respiratory diseases 5,6,29,30 and cancer. [19] [20] [21] 26 Thus, patients diagnosed with these comorbidities should have a closer medical follow-up.

The risk of thromboembolic events in oncologic patients affected by COVID-19 seems to be considerably increased, especially in older patients and those with other important comorbidities (including pulmonary illness). 40, 41 That is partly due to the cancer itself, once cancer can directly influence the presence of hypercoagulability that is responsible for the clinical events of vascular occlusion. 42 Furthermore, the effects of antineoplastic therapy, supportive drugs, such as steroids, and the immunosuppressive properties of cancer itself might be responsible for this higher thromboembolic risk. 42, 43 The treatment of cancer patients with COVID-19 is quite challenging, due to their vulnerable status and the aggressive nature of their underlying disease. 44 Considering that, the European Society for Medical Oncology states that prophylaxis of thromboembolic events should be continued in accordance with existing guidelines. 40 Moreover, proper and preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer, and to effectively manage those who are infected by the virus. These actions are pivotal, since inpatients with cancer infected by SARS-CoV-2 have high chance of mortality. 45 There are many types of thrombotic diseases found in patients affected by COVID-19; however, the most prevalent are VTE, 22 PE, 5, 20, 21 and arterial and venous thromboembolism. 6, 16 This prevalence can vary according to the type of tissue that the SARS-CoV-2 infect, presence of systematic diseases of COVID-19 patients, and genetic and epigenetic factors inherent to the host. 46 In this regards, a recent study reported that lung parenchyma was the most usual site for thrombotic events found in patients with COVID-19, using computed tomography (CT) scanner for diagnostics. 26 Though the precise mechanisms of COVID-19-associated pulmonary emboli and lung microcirculatory thrombotic disease have not been clarified, some mechanisms related to infection, inflammation and coagulation are probably involved. When SARS-CoV-2 infects cells expressing the surface receptors ACE-2, the virus is released inside the host cells, promoting pro-inflammatory apoptosis, triggering oxidative stress and producing pro-inflammatory cytokine and chemokine which are also released from neighbouring cells. The tissue factor, generally hidden in the subendothelium, is upregulated on endothelial cells, leukocytes and platelets, leading to activation of the extrinsic and intrinsic coagulation paths for thrombin production. Subsequently, thrombin binds to protease-activated receptors to promote fibrin formation, activating platelets and allowing clot stabilization. Additionally, blocked small lung blood vessels are expected to contain fibrin, platelets and coagulation factors. 47 The most frequently investigated prognostic factor for thrombotic events in COVID-19 patients was D-dimer levels, which was evaluated in 70% of the studies. 5, 14, [17] [18] [19] [23] [24] [25] [26] 28, 30, 31 Based on these results of the present review, D-dimer levels can be considered a central prognostic factor for thrombosis and inflammatory conditions in patients with COVID-19. However, D-dimer precise values are different and varied among the studies included in this work. Thus, more randomized studies, notably observational studies with bigger sample sizes and adequate control groups, are essential to clarify the role of this factor on predicting thrombotic complications in COVID-19 patients.

Classic anticoagulants from heparin family were the main medication used for thrombotic events complications due to COVID-19 disease. 48 Averbe et al 15 showed that heparin was associated with lower mortality. In addition, there are scientific evidences that chronic anticoagulation therapy at admission was associated with a lower risk of VTE. 20, 21 Moreover, after increasing the thromboprophylaxis, patients with COVID-19 showed a significant time-related decrease in fibrinogen and D-dimers levels. 25 On the other hand, there are also scientific evidences that the use of thromboprophylaxis cannot significantly reduce the risk of TE and DVT. 6, 17 Still, taken all these findings together, it is suggested considering both systematic screening of TE and early therapeutic anticoagulation in severe ICU COVID-19 patients with the urgent need to improve specific VTE diagnostics, and investigate the efficacy and safety of thromboprophylaxis in COVID-19 patients. [22] [23] [24] 27 Concerning the quality analysis, observational investigations present different study designs, which is associated with different research purposes. The bias related to case-control and cohort studies brings great difficulty for inferencing the results to other population and groups. 49, 50 The requirement of responses to COVID-19 and the problem related to this SARS-CoV-2 pandemic may be directly assigned to the bias identified in the different articles and experimental designs.

A meta-analysis was also performed in order to help identify possible quantitative prognostic factors for COVID-19-related thrombotic events and to support physicians on the best clinical scenario and timing for prescribing anticoagulants agents. With the quantitative analysis, thrombotic events might be expected in COVID-19 patients with D-dimer values above 3.17 µg/mL. In addition, it may be considered that neutrophils count and Creactive protein levels were not prognostic factors to thrombotic events in COVID-19 patients. Finally, COVID-19 patients with coagulopathy were 2.23 years older than COVID-19 patients without thrombotic events. Nonetheless, due to high level of heterogeneity in age, these data can be classified as unreliable. This high level of heterogeneity on age might be explained by the dissimilar approaches on managing the pandemic adopted by different medical staff in the world. 51 Still, coagulopathy associated with SARS-CoV-2 appears to be more frequent in patients older than 60 years.

Even so, limited information remains on SARS-CoV-2 and its relationship with thrombotic conditions. Suitable diagnostics examinations and appropriate therapies should be investigated by further randomized studies, including in vivo experiments with different animal models and observational studies to establish other reliable prognostic factors and guidelines for feasible and effective patients' treatments.

COVID-19 patients may develop thrombotic events if they are older than 60 years and if they present D-dimer levels above 3.17 µg/mL. It is suggested that D-dimer levels should be assessed for early diagnosis of thrombotic events in COVID-19 patients. Some comorbidities, such as hypertension, cardiovascular diseases, diabetes, respiratory diseases, chronic kidney disease and active cancer, are also relevant and require attention in COVID-19 thromboembolic events.

Clearly, investigation and efforts towards establishing the profile of COVID-19 patients with higher risk for thrombotic events are needed in order to guide enhanced clinical and therapeutic approaches and to increase chances of inpatients survival.

to acknowledge CAPES for financing, in part, this study (Finance Code 001). ABO, FLB LSS and TMF would like to thank The São Paulo Research Foundation (FAPESP) for the grants n. 2018/18440-0 and 2020/07110-0; 2019/08375-0; 2019/26066-4; and 2021/01191-0, respectively.

There is no conflict of interest involving any author in the present study.

Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: diagnostic and therapeutic perspectives (Review)

General's Statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV)

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

COVID-19 and its implications for thrombosis and anticoagulation

Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

A catalogue of reporting guidelines for health research

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis

OCEBM levels of evidence system

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

The association between treatment with heparin and survival in patients with Covid-19

Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients

DVT incidence and risk factors in critically ill patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of venous thromboembolism in hospitalized patients with COVID-19

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease?

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Neutrophil extracellular traps in COVID-19

The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

COVID-19 e Estado de Hipercoagulabilidade: Uma Nova Perspectiva Terapêutica

Coagulation and sepsis

Contribution value of coagulation abnormalities in COVID-19 prognosis: a bright perspective on the laboratory pattern of patients with coronavirus disease 2019

Spectrum of vascular involvement in coronavirus disease 2019 pneumonia-findings on CT perfusion

In vivo demonstration of microvascular thrombosis in severe Covid-19. medRxiv

COVID-19 and comorbidities: a systematic review and meta-analysis

Supportive care in patients with cancer during the COVID-19 pandemic

Guidelines for treatment and prevention of venous thromboembolism among patients with cancer

Risk assessment for cancer-associated thrombosis: what is the best approach?

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis

COVID-19 and cancer: a comprehensive review

Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies

Genetic and epigenetic factors associated with increased severity of Covid-19

Thrombosis and COVID-19 pneumonia: the clot thickens!

The anticoagulant and antithrombotic mechanisms of heparin

Observational and interventional study design types; an overview

General concepts in biostatistics and clinical epidemiology: observational studies with cohort design

A tale of two city-states: a comparison of the state-led vs civil society-led responses to COVID-19 in Singapore and Hong Kong